Duke Human Vaccine Institute, Durham, North Carolina, USA.
J Virol. 2013 Jun;87(12):6986-99. doi: 10.1128/JVI.00528-13. Epub 2013 Apr 17.
We previously demonstrated that vaccination of lactating rhesus monkeys with a DNA prime/vector boost strategy induces strong T-cell responses but limited envelope (Env)-specific humoral responses in breast milk. To improve vaccine-elicited antibody responses in milk, hormone-induced lactating rhesus monkeys were vaccinated with a transmitted/founder (T/F) HIV Env immunogen in a prime-boost strategy modeled after the moderately protective RV144 HIV vaccine. Lactating rhesus monkeys were intramuscularly primed with either recombinant DNA (n = 4) or modified vaccinia virus Ankara (MVA) poxvirus vector (n = 4) expressing the T/F HIV Env C.1086 and then boosted twice intramuscularly with C.1086 gp120 and the adjuvant MF59. The vaccines induced Env-binding IgG and IgA as well as neutralizing and antibody-dependent cellular cytotoxicity (ADCC) responses in plasma and milk of most vaccinated animals. Importantly, plasma neutralization titers against clade C HIV variants MW965 (P = 0.03) and CAP45 (P = 0.04) were significantly higher in MVA-primed than in DNA-primed animals. The superior systemic prime-boost regimen was then compared to a mucosal-boost regimen, in which animals were boosted twice intranasally with C.1086 gp120 and the TLR 7/8 agonist R848 following the same systemic prime. While the systemic and mucosal vaccine regimens elicited comparable levels of Env-binding IgG antibodies, mucosal immunization induced significantly stronger Env-binding IgA responses in milk (P = 0.03). However, the mucosal regimen was not as potent at inducing functional IgG responses. This study shows that systemic MVA prime followed by either intranasal or systemic protein boosts can elicit strong humoral responses in breast milk and may be a useful strategy to interrupt postnatal HIV-1 transmission.
我们之前的研究表明,以 DNA 疫苗作为初始免疫,然后以载体疫苗进行加强免疫的策略,可在哺乳期恒河猴体内诱导出强烈的 T 细胞应答,但在乳汁中只能诱导出有限的包膜(Env)特异性体液免疫应答。为了提高疫苗在乳汁中的抗体应答,我们以与中度有效的 RV144 艾滋病疫苗相类似的策略,对接受激素诱导的哺乳期恒河猴进行了以 T/F HIV Env 免疫原为主的初次免疫-加强免疫接种。我们对恒河猴进行了肌肉内初始免疫,分别使用了表达 T/F HIV Env C.1086 的重组 DNA(n = 4)或改良安卡拉痘苗病毒(MVA)载体(n = 4),然后肌肉内加强免疫 2 次,使用 C.1086 gp120 和佐剂 MF59。疫苗诱导了大多数接种动物的血浆和乳汁中的 Env 结合 IgG 和 IgA 以及中和和抗体依赖的细胞细胞毒性(ADCC)应答。重要的是,MVA 初免组的血浆对 clade C HIV 变异体 MW965(P = 0.03)和 CAP45(P = 0.04)的中和滴度明显高于 DNA 初免组。随后,我们比较了系统的初次免疫-加强免疫方案与黏膜加强免疫方案,在该方案中,在相同的系统初次免疫后,动物接受了两次 C.1086 gp120 的鼻腔内加强免疫和 TLR 7/8 激动剂 R848 加强免疫。虽然系统和黏膜疫苗方案诱导出了相似水平的 Env 结合 IgG 抗体,但黏膜免疫诱导出了乳汁中明显更强的 Env 结合 IgA 应答(P = 0.03)。然而,黏膜方案在诱导功能性 IgG 应答方面效果并不那么显著。本研究表明,系统的 MVA 初免,然后进行鼻腔内或系统的蛋白加强免疫,可在乳汁中诱导出强烈的体液免疫应答,可能是一种阻断母婴传播的有效策略。